幻覚剤の世界市場：現状分析と予測（2022年～2028年）

世界の幻覚剤の市場規模は、予測期間（2022年～2028年）中に約6％のCAGRで成長すると予測されています。精神衛生に関する国民の意識の高まり、新規治療の探求のための研究開発活動の増加、精神障害の症例数の急増は、幻覚剤市場の成長を促進しています。

当レポートでは、世界の幻覚剤市場について調査しており、市場の洞察、市場動向、競合シナリオ、企業概要など、包括的な情報を提供しています。

目次

第1章 市場イントロダクション

• 市場の定義
• 主な目的
• ステークホルダー
• 制限

第2章 調査方法または仮定

• 幻覚剤市場の調査プロセス
• 幻覚剤市場の調査手法
• 回答者プロファイル

第3章 市場要約

第4章 エグゼクティブサマリー

第5章 幻覚剤市場へのCOVID-19の影響

第6章 幻覚剤市場の収益（2020年～2028年）

第7章 市場の洞察：医薬品別

• リゼルギン酸ジエチルアミド（LSD）
• ガンマヒドロキシ酪酸（GHB）
• ケタミン
• シロシビン
• その他

第8章 市場の洞察：用途別

• 抵抗性うつ病
• アヘン中毒
• 心的外傷後ストレス障害
• パニック障害
• その他

第9章 市場の洞察：流通チャネル別

• 病院薬局
• 小売薬局
• その他

第10章 市場の洞察：地域別

• 北米
  • 米国
  • カナダ
  • その他の北米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋地域
• 世界のその他の地域

第11章 幻覚剤市場力学

• 市場促進要因
• 市場の課題
• 影響分析

第12章 幻覚剤市場機会

第13章 幻覚剤市場動向

第14章 需要側と供給側の分析

• 需要側分析
• 供給側分析

第15章 バリューチェーン分析

第16章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第17章 会社概要

• Jazz Pharmaceuticals plc
• Hikma Pharmaceuticals plc
• Celon Pharma SA
• Cybin Corp.
• Pfizer Inc.
• Numinus Wellness Inc.
• F. Hoffmann-La Roche Ltd.
• Avadel Pharmaceuticals PLC
• PharmaTher Inc.
• NRX Pharmaceuticals Inc.

第18章 免責事項

Global Psychedelic Drugs Market is expected to grow at a significant rate of around 6% during the forecast period. Psychedelic drugs are a class of psychoactive drugs that can produce changes in perception, mood, and cognitive processes. The global psychedelic drugs market is anticipated to witness an uptick owing to the growing awareness among the population regarding mental health, increasing research & development activities for exploring novel treatment options, and a rapid increase in the number of cases of depression, stress, and other mental disorders. For instance, in 2019, nearly 264 million people were suffering from depression and about 50 million people were suffering from dementia across the globe. Also, according to the National Council for Mental Wellbeing, almost half of the adults (46.4%) will suffer from a mental health disorder in their lifetime, and nearly 43.8 million adults (18 years or older) experience a mental illness at any one year. Furthermore, the increasing need for handling excess stress, anxiety, and other mental disorders along with the availability of off-label drugs in the market are also some of the factors that are positively influencing the psychedelic drugs market across the globe.

Jazz Pharmaceuticals plc, Hikma Pharmaceuticals plc, Celon Pharma SA, Cybin Corp., Pfizer Inc., Numinus Wellness Inc., F. Hoffmann-La Roche Ltd., Avadel Pharmaceuticals PLC, PharmaTher Inc., NRX Pharmaceuticals Inc. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with drugs.

Insights Presented in the Report:

"Amongst drugs, LSD category to witness higher CAGR during the forecast period"

Based on drugs, the psychedelic drugs market is segmented into lysergic acid diethylamide (LSD), gamma-hydroxybutyric acid (GHB), ketamine, psilocybin, and others. The lysergic acid diethylamide segment accounted for a significant market share in 2020 and it is estimated that it will grow rapidly during the projected timeframe owing to its ability to increase social interaction, as per a study performed by Researchers from McGill University. Also, LSD is effective in reducing symptoms of stress-related anxiety and depression which in turn is also contributing to the growth of this segment.

"Amongst application, resistant depression to hold a significant share in the market in 2020"

Based on application, the psychedelic drugs market is classified into resistant depression, opiate addiction, post-traumatic stress disorder, panic disorders, and others. The resistant depression segment grabbed a significant market share in 2020. The growth of this segment can be attributed to the increase in the number of people not responding adequately to at least one antidepressant trial of adequate doses and duration.

"Amongst distribution channels, hospital pharmacies to hold a significant share in the market in 2020"

Based on distribution channels, the market is fragmented into hospital pharmacies, retail pharmacies, and others. Among these, the hospital pharmacies to hold a significant share in the market in 2020. This is mainly due to the increasing preference of the patients to avail treatment in hospitals and the easy availability of the medication in hospital pharmacies. Also, the tendency of consumers to visit hospital pharmacies for safe and authorized drugs is also driving the growth of this segment.

"North America to hold a significant share in the market"

For a better understanding of the market adoption of the psychedelic drugs industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. The major factors such as an increase in the population with mental disorders, a rise in investments in research and development for these drugs coupled with technological advancements and raising awareness regarding mental health among the population in the region. As per the National Institute of Mental Health (NIMH) statistics, in 2020, an estimated 52.9 million adults aged 18 or older in the United States had a mental illness.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global psychedelic drugs market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Psychedelic Drugs Market
• 2.2. Research Methodology of the Psychedelic Drugs Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE PSYCHEDELIC DRUGS MARKET

6 PSYCHEDELIC DRUGS MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY DRUGS

• 7.1. Lysergic Acid Diethylamide (LSD)
• 7.2. Gamma Hydroxybutyric Acid (GHB)
• 7.3. Ketamine
• 7.4. Psilocybin
• 7.5. Others

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Resistant Depression
• 8.2. Opiate Addiction
• 8.3. Post-traumatic Stress Disorder
• 8.4. Panic Disorders
• 8.5. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Hospital Pharmacies
• 9.2. Retail Pharmacies
• 9.3. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 PSYCHEDELIC DRUGS MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 PSYCHEDELIC DRUGS MARKET OPPORTUNITIES

13 PSYCHEDELIC DRUGS MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1. Jazz Pharmaceuticals plc
• 17.2. Hikma Pharmaceuticals plc
• 17.3. Celon Pharma SA
• 17.4. Cybin Corp.
• 17.5. Pfizer Inc.
• 17.6. Numinus Wellness Inc.
• 17.7. F. Hoffmann-La Roche Ltd.
• 17.8. Avadel Pharmaceuticals PLC
• 17.9. PharmaTher Inc.
• 17.10. NRX Pharmaceuticals Inc.

18 DISCLAIMER